Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia.

Abstract

The effects of niceritrol, a nicotinic acid derivative, on the levels of HDL-cholesterol (HDL-Ch) and a mixture of VLDL- and LDL-Ch (VLDL- + LDL-Ch) were studied in hyperlipidemic patients. Serum total cholesterol (sTC) and serum triglyceride (sTG) were significantly reduced during niceritrol administration. Lipoprotein electrophoresis showed that niceritrol increased the alpha:beta ratio. HDL-Ch showed a significant increase of 12.5% by the 16th week of therapy. This increase was more marked in patients with lower pre-treatment HDL-Ch levels and significant in patients whose pre-treatment sTG levels were in excess of 200 mg/dl. Females displayed higher pre-treatment HDL-Ch levels (38.5 mg/dl) than males (30.6 mg/dl). However, niceritrol increased HDL-Ch significantly in both groups. At 16 weeks, the VLDL- + LDL-Ch level showed a significant decrease of 9.2%; the HDL-Ch:VLDL + LDL-Ch and HDL-CH:sTC ratios were significantly increased throughout niceritrol administration. Niceritrol is thought to be effective in preventing the development and progression of atherosclerosis because it raises the level of anti-atherogenic HDL-Ch and lowers the level of atherogenic VLDL- + LDL-Ch.

• Authors: M Kibata, M Ishida, K Asano, H Uehara, K Saito, T Fuchimoto, K Ugaki, H Murakami, K Matoba, Y Kotakemori, K Shirai, H Yoshioka, M Nanba, M Yasuda, M Ishizaki, N Kitagawa, K Ikejiri, R Inohara, B J Lee, S Saino, J Sakado, H Matuzaka, K Numata, M Mandai, K Miyake, K Nakamura
• Journal: Atherosclerosis (Atherosclerosis) Vol. 37 Issue 3 Pg. 333-42 (Nov 1980) ISSN: 0021-9150 [Print] Ireland
• PMID: 7458980 (Publication Type: Journal Article)

Chemical References

• Hypolipidemic Agents
• Lipoproteins
• Lipoproteins, HDL
• Lipoproteins, LDL
• Lipoproteins, VLDL
• Nicotinic Acids
• Triglycerides
• Cholesterol
• Niceritrol

Topics

• Cholesterol (blood)
• Female
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Hyperlipoproteinemia Type III (drug therapy)
• Hypolipidemic Agents (pharmacology)
• Lipoproteins (blood)
• Lipoproteins, HDL (blood)
• Lipoproteins, LDL (antagonists & inhibitors, blood)
• Lipoproteins, VLDL (antagonists & inhibitors, blood)
• Male
• Niceritrol (therapeutic use)
• Nicotinic Acids (therapeutic use)
• Triglycerides (blood)